A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)
Latest Information Update: 09 Jan 2024
Price :
$35 *
At a glance
- Drugs Triamcinolone (Primary) ; Triamcinolone
- Indications Osteoarthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Flexion Therapeutics
- 07 Nov 2019 According to a Flexion Therapeutics media release, results from this phase 2a study were published in the peer-reviewed journal, Therapeutic Advances in Musculoskeletal Disease.
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 22 Oct 2018 According to a Flexion Therapeutics media release, results from this trial were presented today at the 2018 American College of Rheumatology (ACR) Annual Meeting.